Career Resources - ClinicaSpace

Advertising on BioSpace eNewsletters

Example eNewsletter #1

Daily - GenePool
Daily - DeviceSpace Daily
Daily - ClinicaSpace Focus
Daily - Deals & Dollars
Weekly - Career Insider
Bi-monthly - Inside Recruiter

BioSpace GenePool

Wednesday, March 25, 2009

ENGINEERING A BETTER DRUG DEVELOPMENT PROCESS THROUGH SCIENTIFIC EXCELLENCE

Aptuit is a pharmaceutical services company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. Since its inception, Aptuit has been engineering a better drug development process by amassing a staff of consummate professionals, breakthrough technologies, facilities and new ideas to offer its clients seamless and globally integrated services.

Aptuit is structured to focus on three major business units - API Development and Manufacturing, Pharmaceutical Development and Manufacturing and Clinical Operations - as well as offering the services of an independent Consulting group. Clients may elect to use all of the comprehensive services of these units, end to end, or select distinctive parts of the mix as needed.

Please visit http://aptuit.com/Services/API.aspx for further information.

• KV Pharmaceutical Company (KV-A) Cuts 1,700 Jobs in North Texas More...

• Oscient Pharmaceuticals Corporation (OSCI) Gets Going Concern Notice; Looking at Alternative Including Sale of Company More...

• NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) and Galderma Pharma S.A. Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions; Galderma to Pay Up to $50 Million More...

• FDA Approves New Indication for Wyeth (WYE)'s (JOBS) TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia More...

• BIOCON, Inc., Bristol-Myers Squibb Company (BMY) (JOBS) Open New R&D Unit in Biocon Park, Bangalore; New Jobs Planned More...

• Human Genome Sciences, Inc. (HGSI) and Morphotek Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology More...

• Tekmira Pharmaceuticals Corporation Extends Research Collaboration With Bristol-Myers Squibb Company (BMY) (JOBS) Through 2009 More...

• Bristol-Myers Squibb Company (BMY) Executives Get Cash Not to Ride Private Jets; 61% Pay Raise to $59 Million More...

More Top News

GENOMICS OF ENERGY AND ENVIRONMENT
MARCH 25-27, 2009
Event Cost: $150

The U.S. Department of Energy Joint Genome Institute (JGI) invites its users and collaborators, as well as prospective new users, to attend the fourth annual JGI User Meeting. This international gathering of researchers with an interest in sequence-based science will offer three days of user presentations, tours, workshops, and poster sessions. This year's meeting will emphasize the genomics of renewable energy strategies, biomass conversion to biofuels, environmental gene discovery, and engineering of fuel-producing organisms. The meeting will feature presentations by leading scientists advancing these topics.

For more information, please visit: http://www.jgi.doe.gov/meetings/usermtg09/index.html

• Doctors Increasingly Close Doors To Drug Reps, While Pharma Cuts Ranks More...

• Licorice May Block Absorption of Organ Transplant Drug, China Medical University More...

• New Drug Agent Knocks Out Multiple Enzymes In Cancer Pathway, University of Illinois Study More...

• The Notch Gene Accelerates Colon Carcinogenesis, CNRS - Faculté de Médecine Study More...

• 'Master Regulator' Of Skin Formation Discovered, Oregon State University Study More...

• Vaccine To Prevent Colon Cancer Being Tested In Patients, University of Pennsylvania School of Medicine Study More...

• Researchers Decipher Blood Stem Cell Attachment, Communication Finding Has Implications For Leukemia Treatment, Artificially Culturing Blood Cells, National Institute of Child Health and Human Development (NICHD) Study More...

• Energy Drinks May Be Harmful To People With Hypertension, Heart Disease, Henry Ford Hospital Study More...

More Featured News

April 16: BayBio2009 | Life Sciences-Navigating the Storm

The BayBio2009 conference focuses on emerging technologies positioned to address today’s and tomorrow’s critical healthcare, manufacturing and environmental concerns, such as skyrocketing health care costs, worldwide food and fuel shortages, escalating manufacturing costs and global competitiveness. The BayBio2009 conference examines novel solutions to which life sciences companies turn in order to survive harsh economic times. The conference focuses on new organizational partnerships that allow life sciences flourish in an environment of increasing financial and regulatory demands. It examines practical application of new ideas and tools in order to increase efficiencies and shorten bench to bedside cycle. Several industry keynote speakers will address issues of importance to the life sciences professionals. A closing reception will provide a perfect opportunity to network with the industry peers.

For more information, visit www.baybio.org

Intellectual Property and Outsourcing in China: Minimizing Risk Whilst Maximizing Return on Investment

• Understand how large pharma, small-sized pharma and biotech companies can benefit from the Chinese pharma market with this report's analysis of the number of companies involved, levels of industry maturity, and existing/projected service offering capabilities.
• Assess the the risk factors associated with outsourcing decisions and measure the suitability of China-based CROs and CMOs with this report's examination of each class of service provider and the key criteria for selecting the most appropriate company, including IPR protection protocols, service quality/capability, cost and geographic location.
• Understand how the IPR protection environment in China is evolving by evaluating the latest regulatory developments and patent application trends for domestic and multinational companies, in addition to this report's market forecasts for outsourcing industry growth to 2015.
• Identify how IPR protection varies across each stage of the R&D process and use case studies of partnerships between Chinese CROs/CMOs and Western companies to measure the success of recent endeavours.

Click Here for More Information

• Biotech Beach (Los Angeles, California)

Tarrot - a Business Unit of Cedars-Sinai Medical Center
Senior Research Scientists
Our Senior Research Scientists plan and implement increasingly complex research in their area of specialization. Responsibilities include providing direction and leadership, project planning, managing day-to-day lab operations and preparing presentations and reports.

• Biotech Bay (South San Francisco, California)

Catalyst Biosciences, Inc.
Staff Scientist II / Sr. Scientist Automation & Screening
Will lead our Automation and Screening Group, which is responsible for integrating automation systems with cutting edge assay technologies and informatics tools to support Catalysts Alterase discovery platform.

• Pharm Country (York, Pennsylvania)

Eli Lilly and Company
Pharmaceutical Primary Care Sales Representative York PA Diabetes Care
Achieve sales growth in territory. Professionally promote Lilly's products to healthcare professionals. Conduct analyses on product and market trends. Develop and execute territory business plans. Coordinate efforts with territory partners in a team environment.

• BioCapital (Ashburn, Virginia)

Howard Hughes Medical Institute
Project Scientist - Electron Microscopy
The Project Scientist will be responsible for guiding the operations of the Electron Microscopy project (in collaboration with Janelia scientists, staff, and visitors), and will identify, manage, and direct the specific tasks required to ensure overall progress toward project goals.

• Genetown (Mansfield, Massachusetts)

Covidien
Manager, Regulatory Affairs
Covidien's surgical device division is seeking an individual to be responsible for worldwide product approval submission activities. This position is responsible for planning and implementing policies, procedures and practices for Regulatory Affairs.

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!

March 30, 2009 Pharm Country Career Fair

BioSpace is pleased to present the Pharm Country Career Fair Monday, March 30, 2009 at the Radisson Valley Forge Hotel.

The Pharm Country Career Fair will provide unlimited opportunities to individuals in the pharmaceutical, biotech, medical device and diagnostics fields. Qualified job seekers and top companies in the industry can come together in one convenient location to interview for hundreds of open positions.

Do not miss the chance to interview with the biopharmaceutical industry's most prestigious companies!

Click here to submit your resume for the Pharm Country Career Fair Now!

Qualified candidates will receive their invitations and confirmation numbers via email 24 to 48 hours after their resumes have been submitted. Pre-screened and accepted candidates must bring a copy of their invitation with confirmation number to the event.

We look forward to seeing you at the Pharm Country Career Fair!

• Pharm Country Career Fair, March 30, 2009
• BioMidwest Career Fair, April 1, 2009
• DeviceSpace Career Fair, April 6, 2009
• BioCapital Career Fair, April 21, 2009
• Biotech Bay Career Fair, May 6, 2009

More information about BioSpace's Career Fairs

BioSpace White Paper
Biotech Career Fairs For Job Seekers 101: Control Your Experience
By June Salvati, BioSpace Director of Events and Corporate Services

SNBL USA, Ltd.
6605 Merrill Creek Parkway
Everett, Washington 98203 U.S.A.
Phone: 425-407-0121 Fax: 425-407-8601
U.S.A.
View Jobs

SNBL USA, Ltd. is a preclinical contract research organization (CRO) that specializes in nonhuman primate (NHP) and small animal research.

More Company Profiles

FREE Subscription to Packaging Digest

Packaging Digest serves manufacturing companies who package products, as well as the wholesale and service industries.

Send questions and comments to the BioSpace NewsBeat Team

Post your News

Post your Jobs

Post your Company Profile

Post your Event

Advertising/Sponsorship

East Coast Office:

West Coast Office:

Editor & Publisher:

Rosemary Do Editorial & Production Staff:

BioSpace.com - Life * Science * Community

WEDDLE's 2008 User's Choice Award for Best Job Boards

• BioSpace is a registered trademark of BioSpace, Inc.
• Please distribute this e-cast freely.
• Credit any excerpts as follows:
Copyright 2009 BioSpace http://www.biospace.com
• While BioSpace and its agents used their best efforts in collecting and preparing the information published herein, we do not assume, and hereby disclaim, any liability for any loss or damage caused by errors or omissions, whether such errors or omissions resulted from negligence, accident or other causes.

If someone forwarded this news to you and you'd like to receive your own copy FREE of charge, simply join the BioSpace GenePool here.

Safely unsubscribe from Biospace.com e-mail at any time by managing your account here or by clicking on the "unsubscribe" link at the bottom of this newsletter.

Example eNewsletter #2

Monthly - BioPharm Executive
Six Ad Secitons
Image and text
Word count = 50

BioPharm Executive

Wednesday, February 25, 2009

Big Pharma's Musical Chairs

The biggest deal of the past month--and what will perhaps prove to be the biggest deal of the year--came just a little too late for inclusion in last month's issue. Pfizer's proposed acquisition of Wyeth represents not just the merger of two major pharmas, but what is really a massive biotech deal--a way for Pfizer to leapfrog ahead in a biologics race where it has traditionally been the laggard.

Wyeth dived into biotech early, when most major drug companies underestimated its potential and viewed the industry as a source of a few niche products to license on attractive terms. But Wyeth--then American Home Products--acquired Genetics Institute way back in the hazy days of 1992. In 1994 it made a major expansion into vaccines through the acquisition of American Cyanamid, its subsidiary Lederle, and its majority ownership in Immunex. The blockbuster arthritis drug Enbrel that Immunex went on to produce continues to be one of Wyeth's biggest revenue drivers to this day.

Of course, Wyeth also has conventional pharmaceuticals--the antidepressant Effexor is its top-selling products. But it is also facing a lot of the same patent expiration and pipeline productivity problems plaguing other major pharma companies.

Whether this turns out to be a good deal or not depends a lot on More...

--Karl Thiel

More By Karl Thiel

It's been a tough month for BioMarin Pharmaceutical, a darling of investors that had until recently shaken off many of the woes facing the rest of the market. But things began to turn in early January when it took an 11th-hour bet on La Jolla Pharmaceuticals' lupus drug Riquent...and subsequently lost. No big deal there; BioMarin had only put $15 million into the deal, recognizing it as a long shot. But the bad mojo already began a week before the Riquent results, when the company also saw its peripheral artery disease drug fail in phase 2. That didn't overly upset investors either, but when the third piece of bad news came in--a lukewarm projection for revenue growth in 2009--investors headed for the exits.

Wall Street has been kinder to InterMune, which reported pivotal data on pirfenidone, a potential blockbuster drug for idiopathic pulmonary fibrosis, a disease with no real current treatment. The data was mixed, but investors are counting on the desperate need for a new drug to sway regulators. -KT

InterMune, Inc. (ITMN) Lung Drug Meets Goal in Trial, Shares Rise +36% on Tuesday at Market Close
More...

La Jolla Pharmaceutical Company (LJPC) and BioMarin Pharmaceutical Inc. (BMRN) (JOBS) Stop Developing Lupus Drug
More...

BioMarin Pharmaceutical Inc. (BMRN) Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
More...

ViroPharma Incorporated (VPHM) Stops Antiviral Drug Late-Stage Study
More...

Vical Incorporated (VICL) (JOBS) Reports Positive Bird Flu Vaccine Trial Data
More...

Amgen (AMGN) (JOBS) Says Motesanib Lung Cancer Trial to Resume
More...

More Bench To Clinic News

Ad Space #1

Career Opportunities in Biotechnology and Drug Discovery
Starts March 3 in Redwood City. Identify a biotechnology career path that best suits your interests, skill sets, and career goals in this five-week course. Through guest lectures, you develop an understanding of a variety of career paths in biotech including venture capital, sales and marketing, business development, clinical and regulatory affairs, and project management.

Aptuit is a pharmaceutical services company focused on streamlining and supporting the drug development process for biotech and pharma innovators. Aptuit has been engineering a better drug development process by amassing a staff of consummate professionals, breakthrough technologies, facilities and new ideas to offer its clients seamless and globally integrated services.

Okay, Tom Daschle is out, but who is in as the likely nominee for Secretary of Health and Human Services? The name of Kansas Governor Kathleen Sebelius is getting a lot of buzz as the likely candidate (though some disagree). Sebelius is a popular politician and has in the past removed herself from Cabinet post consideration so she could work on problems in her home state. If she changes her mind and gets the nod, we can probably be sure that her tax records are in order. Still no definitive word on an FDA Commissioner--scrambling for a new HHS Secretary is doubtless a big distraction.

Meanwhile, GlaxoSmithKline made headlines around the world with its decision to lay off 6,000 to 10,000--a tough blow at a time when even departing Pfizer execs are seeing their severance packages significantly reduced (but still pretty darn lavish compared to us mere mortals). -KT

Official: Sebelius Near Top for Health Post
More...

GlaxoSmithKline (GSK) to Cut 6,000 Jobs
More...

Vertex Pharmaceuticals Incorporated (VRTX) (JOBS) CEO to Retire, Clearing Way for M&A Deal
More...

Savient Pharmaceuticals, Inc. (SVNT) Terminates CFO; David G. Gionco Named as Replacement
More...

Telik, Inc. (TELK) Implements Reorganization to Focus Resources Toward Drug Development Pipeline; Reduces Workforce by 44%
More...

More Career Track News

Ad Space #2

Major Webcast Auction: Surplus Lab Assets from a Leading Drug Discovery and Development Facility. February 26, 2009. All Bidding via the Web. Webcast Bidding Starts at 11am ET.
www.equipnet.com/labwebcast5.

Solvias: BioPharmaceutical Analysis. Our biopharmaceutical services begin with our capability to understand the composition of your drug product or substance. At the heart of our services are method development and validation of QC and stability-indicating methods under cGMP, according to ICH guidelines. More...

It's no surprise that all those "bargains" out there have created a little tension between shopper and shoppee. Roche has gone hostile in its bid to acquire Genentech, while the latter suggests its majority owner's buyout price is about 30% too low. CV Therapeutics has said "no thanks"...twice now...to an unsolicited bid from Astellas, which may not be going hostile simply because of an existing standstill agreement between the companies that forbids it. Avigen continues to spurn the advances of Biotechnology Value Fund while it has yet to comment on a competing offer from MediciNova. EXACT Sciences wiggled out of a hostile takeover from Sequenom by selling assets to Genzyme. It's just business--let's hope there are the minimum of raw feelings out there--but this is somewhat unfamiliar territory for the biotech industry. -KT

Novartis AG to Pay Portola Pharmaceuticals, Inc. $75 Million for Anti-clotting Drug; Portola to Receive $500 Million in Potential Milestone Payments Plus Royalties on Future Sales
More...

Lundbeck to Buy OVATION Pharmaceuticals, Inc. (JOBS) for up to $900 Million in Cash
More...

GlaxoSmithKline (GSK) Pays Up to $450 Million for Idenix Pharmaceuticals, Inc. (IDIX) (JOBS) AIDS Drug
More...

CV Therapeutics, Inc. (CVTX) (JOBS) Rejects Astellas Pharma Inc.'s (JOBS) Bid
More...

Merck & Co., Inc. (MRK) (JOBS) to Pay $130 Million to Insmed Incorporated (INSM) in Biologics Deal
More...

Cephalon, Inc. (CEPH) Exercises Option to License Worldwide Rights to ImmuPharma plc (IMM.L) Product, Lupuzor
More...

More Golden Handshakes News

Ad Space #3

• Biotech Bay (Santa Barbara, California)

Allergan Inc.
VP, Regulatory Affairs -- Allergan Medical
The Vice President, Regulatory Affairs will have global responsibility for all aspects of Allergan Medicals interactions with the FDA, EMEA and other global regulatory agencies and will be the Divisions primary voice to regulatory authorities.
More...

• Biotech Beach (San Diego, California)

REVA Medical Inc.
VP, Quality Assurance and Regulatory Affairs
The Vice President of Quality Assurance and Regulatory Affairs will direct the company's quality management program including implementation and maintenance of total quality management principles and tools to promote continuous improvement of systems, product and service quality.
More...

• Southern Pharm (Huntsville, Alabama)

CFD Research Corporation
Vice President -- Biomedical Technologies
Leading the current research and technology development group, by overseeing current projects, facilitating larger contracts and collaborations, assessments of promising concepts and technologies, development of intellectual property, technology transitions and commercialization, and overall growth of the group.
More...

• Pharm Country (Bridgewater, New Jersey)

ImClone Systems Incorporated
Associate Vice President
Provide medical oversight and clinical strategy for oncology pipeline activities. Clinical interface with other departments including pre-clinical, regulatory and marketing; clinical liaison with licensing partners, investigators, and consultants.
More...

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!

Ad Space #4

BayBio--BioSpace Career Fair
BayBio and BioSpace are teaming up to provide a career fair specifically for BUSINESS professionals in the biotech, pharma, and medical device industries. Unlike BioSpace's typical career fairs which are geared towards scientific professionals, the BayBio--BioSpace Career Fair is intended for the BUSINESS side of the industry.

Genetown Career Fair
BioSpace is pleased to present the Genetown Career Fair on Thursday, February 26, 2009 at the Sheraton Boston from 2pm - 7pm. Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, and medical device companies in the Boston area.

The ongoing dance between Roche and Genentech is turning into a mosh pit scrum. Roche went hostile in its bid for the remaining 44% of Genentech it doesn't own, reducing its offer from $89 per share to $86.50 per share and taking it as a tender offer directly to shareholders. Genentech has asked investors to pay no attention to these missives while it thinks up its next move. It turns out, according to filings, that Genentech wanted $112 per share, based on some fairly rosy assumptions about the future, so there's a pretty big gap to bridge. Roche, more than many pharma companies, is known for playing hardball in its negotiations, but getting what it wants means raising money. Thus, a $16 billion financing that not just any old company could pull off these days. Looks like they're serious.

Meanwhile, there was actually an IPO in the last month! Mead Johnson Nutrition isn't exactly an unknown entity; it's a unit of Bristol Myers-Squibb widely known for its Enfamil infant formula, and BMS is holding onto 85% of the company. Still, it priced at the top end of its expected range and has gone up since then. That's something, isn't it? -KT

Roche Holding AG (RHHBF.PK) Sells $16 Billion in 6-Part Debt Sale
More...

Mead Johnson Nutrition Company $720 Million IPO Breaks 12-week Drought
More...

Vertex Pharmaceuticals Incorporated (VRTX) Says It Plans to Sell 10 Million New Shares
More...

Sopherion Therapeutics, Inc. Secures $55 Million in Series C Funding
More...

Algeta Raises $35 Million in a Private Placement
More...

More Money Talk News

Ad Space #5

Allicense 2009
For this 13th annual meeting of the Allicense conference we'll examine the best practices and most innovative approaches for forging the alliances that bridge the gap between biomedical innovation and commercialization. This year we are pleased to welcome Corey Goodman, president of Pfizer's Biotherapeutics More....

CHI: Biomarker World Congress is dedicated to all areas of biomarker research. The Congress offers a balance of scientific sessions covering the latest research and strategic presentations. Now in its fifth year, the Biomarker World Congress is the leading annual meeting delivering a cutting-edge agenda, 500+ senior delegates, and a sold-out exhibit hall.

Genentech is trying to convince Roche it is worth $112 a share, but emerging troubles with Raptiva--now a total of three confirmed and one potential case of progressive multifocal leukoencephalopathy (PML)--isn't helping its case. The European Medicines Agency has recommended suspending marketing authorization for the drug and FDA has issued a public health advisory. This isn't a critical setback to the maker of Avastin, and Biogen Idec has already tread these waters with Tysabri and proven it is possible to keep marketing approval and patient demand. But it's may strain Genentech's internal valuation models a bit. -KT

FDA Orphan Drug Designations Are On the Rise
More...

Psoriasis Drug Raptiva Tied to Brain Infection
More...

California Supreme Court Refuses to Review Appeals Court Ruling that Brand-Name Drug Manufacturer Can Be Liable for Injuries the Patient Sustained while Taking Generic Version of the Drug
More...

More Legal Briefs News

Ad Space #6

Divestment Strategies: Pharma is divesting in order to grow
Understand why in the current financial climate pharma companies are divesting assets, and the drivers and resistors of divesting and acquiring. Insight in to how best to divest an asset, prepare a company for de-integration and set up transfer agreements to ensure a smooth asset transition.

Device Career Network: DeviceSpace and Medical Device Link Launch Dynamic, Online Career Center. Partnership forms Device Career Network, a targeted community of more than 60,000 medical device and diagnostics professionals.
www.DeviceCareerNetwork.com

The stakes couldn't have been much higher. With prasugrel, Eli Lilly can reinvent itself--steal the thunder from the Bristol Myers-Squibb/Sanofi-Aventis drug Plavix and take a huge chunk of a $5 billion-and-growing pie. Without it...well, Lilly could just conceivably end up as one of those "major acquisitions" other drug company execs are talking about. Good news for Indianapolis: The panel backed the antiplatelet drug, with the Cleveland Clinic's celebrity cardiologist Steve Nissen lending his support. Meanwhile, Savient lost the gout race (now there's a mental image) to Teijin and Takeda. The first new therapy in 40 years will come from the Japanese pharmas. -KT

U.S. Panel Backs Eli Lilly and Company (LLY) (JOBS), Daiichi Sankyo Co Ltd. (JOBS) Anti-clotting Drug
More...

Teijin Pharma and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announce ULORIC Receives FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout
More...

Savient Pharmaceuticals, Inc. (SVNT) Says FDA Extends Review of Gout Drug
More...

European Medicines Agency Recommends Suspension of Marketing Authorization for Genentech, Inc. (DNA) and Merck Serono's Raptiva(R)
More...

Mylan Inc. (MYL) Receives FDA Approval for First-to-File Generic Depakote(R) ER
More...

More Rockville Files News

Karl Thiel is an analyst for The Motley Fool, a columnist for BioWorld Today, and a contributor to Nature Biotechnology. He lives in Portland, Oregon.

You may contact Karl Thiel at Karl.thiel@biospace.com.

East Coast Office:

West Coast Office:

BioSpace.com - Life. Science. Community.

If someone forwarded this news to you and you'd like to receive your own complimentary monthly copy, simply join the BioSpace BioPharm Executive here.

Safely unsubscribe from Biospace.com e-mail at any time by managing your account here.